Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Maraviroc Receives FDA Approval
 

The U.S. Food and Drug Administration (FDA) approved the antiretroviral drug maraviroc on August 6, 2007. Maraviroc, the first in a new class of oral HIV therapies known as CCR5 inhibitors, is approved for use in adult HIV-infected patients. CCR5 inhibitors work by binding to receptors on the surface of cells, preventing HIV from latching on and inserting itself into other uninfected cells. This effectively hinders the infected cells’ ability to replicate. The drug is manufactured by Pfizer Inc., a global pharmaceutical company headquartered in New York.
Read the entire FDA release.

Source: FDA news release dated August 6, 2007

 

This section of our Web site is sponsored by: